New eye drug trial aims to save sight in Hard-to-Treat AMD
NCT ID NCT07187804
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests faricimab, a drug injected into the eye, for people with type 3 wet age-related macular degeneration (AMD), a condition that can cause rapid vision loss. Over 76 weeks, 30 participants will receive initial monthly doses, then a personalized schedule where injections are spaced out if the eye stays stable. The goal is to see if this approach better preserves vision and reduces fluid buildup compared to standard care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- faricimab (injected into the eye)
- What this could lead to
- If successful, this could offer a more effective and convenient treatment schedule for a hard-to-treat form of wet age-related macular degeneration, potentially preserving vision longer.
- What could go wrong
- This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. The treatment involves repeated eye injections, which carry risks like infection or retinal damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION (ARMD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Kim's Eye Hospital
Seoul, 150-034, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Higher-Dose eye injection may help wet AMD patients who Didn't respond to standard treatments
- Eye fluid clues may predict who benefits from vision-saving injections
- New eye injection could change treatment for wet AMD
- Eye injection burden varies by disease, study finds
- Gene therapy could end frequent eye injections for wet AMD
- New eye drug tiespectus takes on aflibercept in major wet AMD trial